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Abstract
Objective—This study aims to examine trajectories of attention-deficit/hyperactivity disorder 
(ADHD) symptoms in the Longitudinal Assessment of Manic Symptoms (LAMS) sample.
Method—The LAMS study assessed 684 children aged 6-12 with Kiddie-Schedule for Affective 
Disorders and Schizophrenia (K-SADS) and rating scales semi-annually for 3 years. Though 
selected for elevated manic symptoms, 526 had baseline ADHD diagnoses. With growth mixture 
modeling (GMM), we separately analyzed inattentive and hyperactive/impulsive symptoms, 
covarying baseline age. Multiple standard methods determined optimal fit. Chi-square and 
Kruskal-Wallis analysis of variance (ANOVA) compared resulting latent classes/trajectories on 
clinical characteristics and medication.
Results—Three latent class trajectories best described inattentive symptoms; 4 classes best 
described hyperactive/impulsive symptoms. Inattentive trajectories maintained their relative 
position over time. Hyperactive/impulsive symptoms had 2 consistent trajectories (least and most 
severe). Another (4.5%) started mild, then escalated; and a fourth (14%) started severe but 
improved dramatically. The improving trajectory had the highest rate of ADHD and lowest rate of 
bipolar diagnoses. Three-fourths of the mildest inattention class were also in the mildest 
hyperactive/impulsive class; 72% of the severest inattentive class were in the severest hyperactive/
impulsive class; but the severest inattention class also included 62% of the improving hyperactive-
impulsive class.
Conclusion—An ADHD rather than bipolar diagnosis prognosticates a better course of 
hyperactive/impulsive, but not inattentive, symptoms. High overlap of relative severity between 
inattention and hyperactivity/impulsivity confirms the link between these symptom clusters. 
Hyperactive/impulsive symptoms wane more over time. Group means are insufficient to 
understand individual ADHD prognosis. A small subgroup deteriorates over time in hyperactivity/
impulsivity and needs better treatments than currently provided.
Keywords
ADHD; GMM; longitudinal symptoms; inattention; hyperactivity/impulsivity
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder 
manifested in symptoms of inattentiveness, disorganization, distractibility, overactivity, and 
impulsiveness. The DSM, both VI and 5,1-2 lists 9 inattentive and 9 hyperactive/impulsive 
symptoms. Most follow-up studies of participants diagnosed with ADHD as children show 
persistence of inattentive symptoms (Inattn) and considerable waning of hyperactive-
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impulsive symptoms (HA/Imp), with more persistence of impairment than of symptoms and 
worse outcomes than comparison participants without ADHD.3-6 In a twin study, 
hyperactivity/impulsivity (HA/Imp) in middle childhood predicted inattentiveness (Innattn) 
in adolescence, but Inattn in childhood did not predict HA/Imp in adolescence.5
Although most follow-up studies simply reported the mean symptom levels or diagnostic 
proportions for the sample at various follow-up times, some tracked latent classes of 
symptom trajectories over time with growth mixture modeling (GMM). A literature search 
found 6 reports showing ADHD latent class symptom trajectories over time (Table 1), using 
various measures of symptom severity, varied foci (inattention, hyperactivity, all ADHD 
symptoms, or a proxy for DSM symptoms) and various follow-up times, from 12 hours in a 
laboratory school to 12 years. The most common number of latent classes found was 3.
The largest GMM sample tracked 12,486 twins and 1,346 single births from age 6 to 12, 
focusing on inattentive symptoms separately by sex.7 It identified 3 trajectories in both boys 
and girls (stable low, low-increasing, and high-decreasing, the latter two crossing). The only 
apparent difference by sex was that trajectories started and ended lower for girls, with 
similar slopes. Trajectories were also similar for twins and singletons.
The second-largest sample was a community sample of 754 children (half high-risk) 
recruited in kindergarten.8 It examined the relationship of ADHD symptoms to early illicit 
drug use. It also revealed a 3-class model for 6-year ADHD symptom trajectories. Two 
started high: one with symptom decrease in third grade, then increase in 6th grade, and one 
with increase, then decrease. A third class showed no or minimal symptoms throughout. 
Class 1 (decrease, then increase) demonstrated significantly earlier onset of illicit drug use 
than Class 3; Class 2 (increase, then decrease) was not significantly different from either of 
the other classes in drug use. The results held when conduct problems were covaried.
The largest diagnosed ADHD sample (N=486, age 7-10 at baseline, all with combined type 
ADHD) was from the National Institute of Mental Health (NIMH) Multimodal Treatment 
Study of Children with ADHD (MTA), done on the mean of all 18 DSM-IV symptoms.9 It 
also resulted in 3 latent classes over a 3-year period, all starting prior to treatment at an item 
mean of about 2.0 (range 1.9-2.1) on a 0-3 severity scale and influenced by the 14 months of 
treatment provided to three quarters of the MTA children. Class 1, 34% of the sample, 
improved by only about -0.4 point (item mean) with 14 months of treatment, but maintained 
that gain at 24 months and improved further by 36 months, suggesting a good eventual 
prognosis. Class 2, 52% of the sample, was slightly milder at baseline than the other two 
classes (1.9 vs. 2.1), showed a sharp symptom decline to about 0.8 with 14 months of 
treatment, and consistently maintained that improvement to 36 months. Class 3, 14% of the 
sample, showed as much improvement as Class 2 with 14 months of treatment but then 
regressed steadily and by 36 months had almost returned to baseline.
Jester et al. tracked hyperactivity/inattention and aggressive behavior in 335 children of 
alcoholic and nonalcoholic fathers for 12 years from aged 3-5 to aged 16 at 3-year intervals 
in a high-risk prospective study of substance use and comorbid problems.10 Aggressive 
behavior decreased throughout childhood and adolescence, but HA/Inattn behaviors 
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remained constant. GMM found 2 trajectories for HA/Inattn and 2 for aggression. The worse 
HA/Inattn trajectory was predicted by lower emotional support and intellectual stimulation 
by parents. The worse aggression trajectory was predicted by family conflict and lack of 
cohesiveness. When 4 classes were developed from a 2X2 combination of the 2 
hyperactivity/inattention and 2 aggression trajectories (healthy=low on both trajectories; 
HA/Inattn =high onHA/Inattn , low on aggression; aggressive=high on aggression, low 
onHA/Inattn ; and comorbid, high on both), the aggressive and comorbid classes had the 
highest risk of alcohol problems, and the healthy class, the lowest.11
Sonuga-Barke et al. found 3 trajectories of ADHD symptoms over a 12-hour day (low and 
stable, high and increasing, and intermediate and increasing) in 184 children with diagnosed 
ADHD while taking placebo in a laboratory school study.12 This demonstrated variability in 
diurnal course. The 3 classes responded differentially to the two methylphenidate 
preparations being compared.
Although not using GMM, Lubke et al. derived latent class attention-problem profiles 
separately at 7, 10, and 12 years of age in several thousand children.13 Three classes were 
found at each age. The most severe class contained all the children who had diagnosed 
combined-type ADHD and the mild class had no diagnosed ADHD. Inspection of the graphs 
for the 3 ages suggests waning of HA/Imp problems, but not concentration problems.
The Longitudinal Assessment of Manic Symptoms (LAMS) study provides another 
longitudinal sample large enough (N=684) for a GMM analysis.14-15 Although not selected 
for ADHD, 538 of the 707 children with baseline assessments in this sample had an initial 
ADHD diagnosis (307 combined type, 108 inattentive type; 49 hyperactive-impulsive type, 
74 not otherwise specified, or NOS). See “Method” for further details. This sample differs in 
four ways from most of the others: 1) Unlike the Robbers, Malone, Jester, and Lubke 
samples,7-8,10-11,13 it has rigorous standardized clinical diagnoses of ADHD. 2) However, 
unlike the Swanson and Sonuga-Barke samples,9,12 it was not selected for a diagnosis of 
ADHD, but for related (manic) symptoms and therefore includes some children without an 
ADHD diagnosis but with some ADHD symptoms. This could provide some insight into 
what happens with subdiagnostic ADHD symptoms.16-17 3) The age range (6-12 at entry) is 
broader than all except Sonuga-Barke’s.12 4) Assessment points --every 6 months-- are more 
frequent than all except Sonuga-Barke’s.12 Thus the LAMS sample allows us to expand on 
previous reports in several ways, including examination of Inattn and HA/Imp separately, 
across a broad range of age, diagnoses, and initial severity, with more intensive repetition of 
follow-up assessment. We tested the following hypotheses:
1. Without the influence of a consistent and specified study treatment, there will be 
less visibly dramatic differences in the shapes of latent class trajectories in this 
sample than in the MTA; in particular, the 14-month inflection seen in the MTA 
trajectories will not be seen.
2. Children with the most severe initial symptoms will remain the most severe at the 
end of three years; i.e., initial relative severity will be the strongest determinant of 
relative end severity.18
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3. HA/Imp symptoms will decrease more over time than Inattn symptoms, consistent 
with developmental trends for improvements in inhibitory mechanisms,19 as well 
as trends identified in prior ADHD research.
4. ADHD diagnoses will be significantly less prevalent in the lowest ADHD symptom 
severity class.
Method
Study Sites and Participant Ascertainment
The data analyzed here are from the first three years of the NIMH-supported LAMS study, 
approved by the Institutional Review Boards at each of the four university-affiliated LAMS 
sites. Written informed consent and assent were obtained before any study procedures.
The LAMS study is a 4-site epidemiological study designed to track a cohort of children 
aged 6-12 selected mainly for having elevated symptoms of mania (ESM+), to determine 
characteristics of pediatric bipolar disorder and predictors of eventual development of 
bipolar disorder (BD).14 Annual assessments included a comprehensive diagnostic and 
functional battery, with abbreviated, more focused assessments at the 6-month intervals.
Participants were recruited from 9 child outpatient mental health clinics (2 in Northeast 
Ohio, 1 in Pittsburgh, 5 in Columbus, and 1 in Cincinnati). Patients aged 6 to 12 years 
attending new evaluations at the respective clinics were eligible for screening. Their parents/
guardians were asked to complete the Parent General Behavior Inventory – 10 Item Mania 
Scale (PGBI-10M) to screen for ESM+,20-21 defined as a score of 12 or more out of a 
possible 30. PGBI-10M items were scored 0-3 (none to most severe), describing hypomanic, 
manic, and biphasic symptomatology. They discriminate BD from other diagnoses.20-21 All 
patients whose parent/guardian rated them at or above 12 (ESM+) were invited to 
participate. In addition, a demographically matched comparison group of patients with 
scores 11 or lower (ESM-) were selected. Of the 707 who had baseline assessment, 685 were 
eligible to continue longitudinally (those with intellectual or developmental disability were 
excluded after baseline assessment).
Assessments
All participants were administered the Schedule for Affective Disorders and Schizophrenia 
for School-Age Children-Present and Lifetime Episode (KSADS-PL),22 with additional 
mood onset and offset items derived from the Washington University in St. Louis 
KSADS.23-24 Diagnoses of bipolar spectrum disorders (BPSD), depression, anxiety, ADHD, 
and disruptive behavior disorder were derived from the KSADS; and proxy diagnoses of 
disruptive mood dysregulation disorder (DMDD) were taken from analyses by Axelson et 
al.25
The LAMS study used the following criteria for bipolar disorder-not otherwise specified 
(BP-NOS): (a) elated mood plus two associated manic symptoms (e.g., grandiosity, 
decreased need for sleep, pressured speech, racing thoughts, increased goal-directed activity, 
etc.), or irritable mood plus three associated symptoms; (b) change in the participant’s level 
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of functioning (i.e., increase or decrease of episodes); (c) symptoms present for at least 4 
hours within a 24-hour period; and (d) at least 4 episodes of 4 hour duration or a total of 4 
days in the child’s lifetime. These criteria were also used in the Course and Outcome of 
Bipolar Youth (COBY) study.26 A licensed child psychiatrist or psychologist reviewed and 
confirmed all diagnoses. In addition, interrater reliability of interviewers was checked by 
rating taped administrations of the K-SADS-PL-W, Children’s Depression Rating Scale-
Revised (CDRS-R),27-28 and the Young Mania Rating Scale (YMRS).29 The kappa for K-
SADS-PL-W psychiatric diagnoses was 0.82 and more specifically, the kappa for bipolar 
diagnoses was 0.93. Demographic information was obtained from parents/guardians. A more 
detailed description of the baseline assessment and a description of the 707 children and 
adolescents with baseline assessments are outlined in Findling et al.15
Psychometric Scales
Manic symptoms were assessed by parent report with the Parent General Behavior Inventory 
–10 Item Mania Scale (PGBI-10M; alpha=.89 in the present sample),20-21 and by interview 
of the child and parent with the Young Mania Ratings Scale (YMRS; alpha=.76).29-33 
PGBI-10M items were scored 0-3 (none to most severe), describing hypomanic, manic, and 
biphasic symptomatology. Examples are: “Has your child experienced periods of several 
days or more when, although he/she was feeling unusually happy and intensely energetic 
(clearly more than your child’s usual self), he/she was also physically restless, unable to sit 
still, and had to keep moving or jumping from one activity to another?” or “Have there been 
periods of several days or more when your child’s friends or other family members told you 
that your child seemed unusually happy or high – clearly different from his/her usual self or 
from a typical good mood?”. This scale discriminates BD from other diagnoses.20-21 Total 
scores range from 0 to 30, and a cut score of 12 identified ESM+ children. Functional 
assessment was measured by the Children’s Global Assessment Scale (CGAS).34 The 
presence and severity of depressive symptoms were assessed using the Child Depression 
Rating Scale-Revised (CDRS-R; alpha=.81).27-28,33 Parent-reported dimensional scores of 
DSM-IV inattentive and hyperactive-impulsive symptoms of ADHD (alpha=.94), symptoms 
of oppositional defiant disorder (ODD; alpha=.92), and symptoms of conduct disorder (CD; 
alpha=.81) were examined with the Child and Adolescent Symptom Inventory-4-Parent 
Version (CASI-4R).35-36 CASI-4R symptoms are rated 0-3, 3 being the most severe; the 
item mean for each symptom cluster is usually analyzed. Medication use and other 
treatments were recorded on the Services Assessment for Children and Adolescents 
(SACA).37 The Parent Stress Survey (PSS), a 25-item parent self-report scale designed to 
assess parental stress due to raising a psychiatrically impaired child,38 was also used. Each 
item has a yes-no response, followed by a Likert scale from 0 (not at all stressful) to 4 (very 
stressful). The total score ranges from 0 (no stress) to 100 (highest stress). Coefficient alpha 
is 0.87.38
Sample Characteristics
Of the 707 children with baseline LAMS assessment, 621 were EMS+ and 86 were ESM.15 
A majority (n=538) had ADHD while a minority (n=162) had a bipolar spectrum disorder 
(BPSD), most of them (n=117) with comorbid ADHD. Thus this sample, not selected for 
ADHD, was dominated by the second-largest group of children with diagnosed ADHD ever 
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followed longitudinally with serial in-person assessments (the MTA started with 579 ADHD 
participants).39 Of the 707 with baseline assessment, 685 are eligible for longitudinal study, 
and of these, 684 have usable ADHD symptom data, 526 with diagnosed ADHD: 107 
inattentive type, 47 HA/Imp type, 302 combined type, and 70 NOS. Of the 684, 178 had a 
proxy diagnosis of DMDD by Axelson et al.25
Statistical Analyses
Using M-Plus 7, we analyzed GMMs separately on the 9 Inattn symptoms and the 9 HA/Imp 
symptoms. Both models included baseline age as a covariate. One of the 685 longitudinal 
participants, a girl with combined type ADHD, had missing ADHD dimensional data for all 
assessment points and was excluded from analyses. Optimal fit was determined by a 
combination of Bayes Information Criteria (BIC, raw and adjusted), Aike Information 
Criteria (AIC), the adjusted Lo-Mendell-Rubin (LMR) likelihood ratio (LR) test, the 
bootstrap LR test, entropy (Table 1) , and consideration of how clinically interesting the 
resulting trajectories were. Three latent classes best described Inattn assessments while four 
latent classes best described HA/Imp assessments. Chi-squared and ANOVA analyses-- 
according to level of measurement-- compared classes on baseline characteristics and 
medication use at each of the 7 assessment points. Due to non-normality of the continuous 
outcome variables, the nonparametric Kruskal-Wallis ANOVA was employed for 
comparison among classes. Cross-tabulation evaluated overlapping membership between 
Inattn classes and HA/Imp classes. Exploratory analyses comparing class characteristics 
used alpha = 0.05 for the omnibus test of each domain and set-wise Bonferroni correction 
for multiple comparisons.
Results
Based on a priori criteria, the model with optimal fit for Inattn was three classes/trajectories, 
and for HA/Imp was four classes/trajectories (Table 1). Inattn trajectories (Figure 1, panel 
A) mainly differed in severity, although there was some modest fluctuation over time in the 
most severe and least severe trajectories. These at first appeared to regress toward the 
middle trajectory, which showed no change, but then, with a significant quadratic term for 
time, trended back toward their own baselines. In contrast, three of the four HA/Imp 
trajectories (Figure 1, panel B) showed the expected symptom decrease over time and with 
different slopes; further, three trajectory slopes crossed. Class 2, the only exception to 
decreasing over time (actually increasing significantly), was <5% of the sample. Of special 
interest is Class 4, which started relatively severe (item mean ~2.2), then declined steeply. 
Unfortunately, this favorable slope was only 14% of the sample. Thus for both symptom 
clusters, Class 1 is the most favorable trajectory (consistently mildest across time) and Class 
3, the least favorable (consistently most severe across time). For Inattn, Class 2 is 
intermediate in severity and consistent over time. For HA/Imp, Class 2 had the least 
favorable slope (0.12, p=0.049; worsening over time) and Class 4 the most favorable slope 
(-0.59, p=0.005; improving notably over time).
Tables 3A and 3B present demographic and clinical comparisons of the different trajectories 
within each symptom domain, and Table 4 presents medication use by time point. Neither 
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Inattn nor HA/Imp classes differed significantly in sex, race, ethnicity, depressive disorder, 
nor anxiety disorder.
Inattn classes differed from each other in 12 ways: 1) the proportion with baseline ADHD 
diagnosis (p<0.001): Class 3 had the most while Class 1 had the fewest, consistent with 
Hypothesis 4; 2) the proportion with baseline disruptive behavior disorder (ODD or CD) 
(p<0.001); Class 1 had the lowest proportion; 3) the proportion with baseline BPSD 
diagnosis (p<0.001); Class 3 had the highest while Class 2 had the lowest; 4) the proportion 
that were ESM+ (p=0.012); Class 3 had the highest while Class 1 had the lowest proportion; 
5) the proportion with proxy DMDD (p=0.006): Class 3 had the highest and Class 1 the 
lowest proportion; 6) manic symptoms as measured on the YMRS and PGBI-10M 
(p<0.001); Class 3 had the highest scores; 7) depressive symptoms on the CDRS-R 
(p<0.001); Class 3 had the highest scores; 8) global functioning, as noted on the baseline C-
GAS (p<0.001); Class 3 had the lowest functioning; 9) parent stress scores (p<0.001: Class 
3 was the highest; 10) baseline age (p=0.028), with Class 3 being the oldest (9.6 years) and 
Class 2 the youngest (9.2 years); 11) the proportion receiving stimulants (p<0.001), with 
Class 1 having the lowest proportion at all times (18-29%, compared to 42-57% in Class 3); 
12) the proportion receiving any medication (p=0.045 to <0.001), again with Class 1 having 
the lowest proportion at all times (42-61%, compared to 67-79% in Class 3).
In summary, Inattn Class 1, with the lowest severity throughout, had the lowest proportion 
of baseline ADHD and disruptive behavior disorder diagnoses, lowest proportion of ESM+, 
lowest proportion of DMDD, lowest rating of manic symptoms, lowest proportion of parent 
stress scores and highest global functioning. Conversely, Class 3, with the most severe 
Inattn ratings over time and oldest age at entry, had the highest proportion of ADHD, 
disruptive behavior disorder, DMDD, and BPSD diagnoses, highest proportion of ESM+, 
worst manic and depressive symptom severity scores, and lowest global functioning.
The four HA/Imp classes differed significantly in nine ways: 1) the proportion with baseline 
ADHD diagnosis (p=<0.001), with Class 4 having the highest rate and Class 1, the lowest; 
2) the proportion with disruptive behavior disorder (p<0.001), with Class 1 having the 
lowest proportion; 3) the proportion with a BPSD diagnosis (p=0.021), with Class 3 having 
the highest and Class 1 the lowest; 4) the proportion of ESM+ (p<0.001), with Classes 3 and 
4 higher than Classes 1 and 2; 5) the proportion with DMDD, with Class 3, the highest and 
Class 1, the lowest; 6) the proportion with manic symptoms as measured on the YMRS and 
PGBI-10M (p<0.001), with Class 1 having the lowest and Class 3 the highest severity; 7) 
global functioning as measured by the baseline C-GAS (p<0.001), with Class 1 the highest 
functioning; 8) parent stress severity (p=0.003), with Class 3 the most severe; and 9) the 
proportion receiving stimulants p<0.001), with Class 3 (46-61%) and Class 4 (46-52%) 
having the highest proportions. The proportion taking any medication was significant only at 
baseline, when Class 1 had the lowest rate (53%).
In sum, Class 1, with the most consistently favorable HA/Imp trajectory, had the lowest 
proportion of ADHD, disruptive behavior disorder, BPSD, and DMDD diagnoses as well as 
second-lowest proportion of ESM+, lowest manic symptom scores, lowest parent stress, and 
highest global functioning. Class 4, which had the steepest decline of HA/Imp symptoms, 
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had the highest proportion of ADHD diagnoses, second-highest proportion of DMDD, and 
the second-lowest proportion of BPSD diagnoses, even though it had the highest initial 
proportion of ESM+.
Cross tabulation of the two latent class groups (Table 5) shows that 77% of the consistently 
mildest Inattn class (Class 1) falls in the consistently mildest HA/Imp class; and 72% of 
Inattn Class 3, with consistently severe symptoms, fell into HA/Imp Class 3, which also had 
consistently severe symptoms. Of note, consistently severe Inattn Class 3 also included 62% 
of the HA/Imp Class 4, which had dramatically improving symptoms.
Discussion
The new GMM latent classes presented here complement and contrast with previous GMM 
analyses. This was the first study to separately track both Inattn and HA/Imp DSM 
symptoms; others tracked either only Inattn symptoms or a composite of Inattn and HA/Imp 
(Table 1). This study had more frequent assessments than any other longitudinal study. In 
contrast to the previous reports, which never exceeded 3 latent trajectories, this study found 
4 HA/Imp trajectories, possibly because it was the only one to separately track the DSM 
HA/Imp symptoms. This demonstrated different courses of the two symptom clusters over 
time.
Inspection of graphs shows that hypothesis 1 is supported: there is no sharp decrement at 
one year as in the MTA. Hypothesis 2, relative initial severity predicting relative end 
severity, is supported for Inattn, but not HA/Imp. Hypothesis 3, HA/Imp symptoms 
declining more than Inattn, is partially supported by a nonsignificant trend; the exception, 
Class 2, was <5% of the sample. Hypothesis 4, ADHD diagnoses rarer in the lowest severity 
classes, was supported.
For the same initial severity of HA/Imp symptoms, an ADHD rather than bipolar diagnosis 
predicts a better trajectory of ADHD symptoms. Inattn symptoms tend to remain at a more 
consistent severity over time than HA/Imp symptoms. Decreasing HA/Imp symptoms were 
associated with a high rate of stimulant medication, possibly confounded with the high rate 
of ADHD diagnosis in the class showing the sharp decrease.
As predicted, LAMS symptom trajectories do not show the sharp improvement at 1 year 
found in the MTA trajectories, resulting from standardized, systematic MTA treatments. In 
the LAMS sample, although medication use differed significantly across classes at all 
assessment points, the change within class did not differ appreciably, except for a moderate 
increase between baseline and 6-month assessment for all classes, with a subsequent 
leveling off. This initial medication increase could have played a role in the classes that 
showed a decline, but would not fit with the classes showing an increase of symptoms. 
Importantly, none of the classes showed an inflection at 6 months that could be attributed to 
the initial medication increase. This difference between MTA and LAMS trajectories might 
be taken as indirect confirmation that improvement noted in the beginning of the MTA 
trajectories resulted from the specific treatment protocols rather than being a common 
course of the disorder. However, this conclusion must be tempered by realization that the 
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LAMS sample was not selected for ADHD with the same initial ADHD symptom threshold 
requirement that could have predisposed the MTA sample to regress to the mean.40
Also as hypothesized, relative initial severity of Inattn predicted relative 3-year severity, but 
the same did not hold true for HA/Imp symptoms over time. Not only did three quarters of 
the HA/Imp trajectories show the expected waning of symptoms over time, but there was a 
slope crossing between Class 2 and Classes 3 and 4, with Class 2 starting lower and ending 
significantly higher (p=0.0001) than Class 4 and higher than Class 3. Thus Class 2 was an 
exception to HA/Imp waning, but it was only 4.5% of the sample. In contrast, the 3 Inattn 
trajectories maintained their relative severity over time without appreciable waning of 
severity. HA/Imp Class 4, with the most favorable slope, had the highest proportion of 
ADHD diagnoses and lowest proportion of BPSD diagnoses, suggesting that HA/Imp 
symptoms resulting from ADHD rather than from BPSD tend to improve over time (at least 
if treated). Class 2, with the least favorable slope and only 31 children, had the second-
highest proportion BPSD, second-lowest proportion ADHD, lowest proportion ESM+, 
second-lowest proportion DMDD, second-lowest parent stress score, lowest proportion 
male, lowest proportion non-Hispanic white, and youngest age, all nonsignificant. It is not 
clear why HA/Imp symptoms increased so dramatically in this small class, but possibilities 
include that the younger age and/or higher proportion of girls and/or minorities allowed 
more maturation-linked development of overlapping symptoms from other disorders.
The overlaps of Inattn classes and HA/Imp classes in Table 5 are for the most part not 
surprising: the most consistently favorable trajectory of one symptom cluster tends to match 
the most consistently favorable of the other, and similarly with the consistently severe 
trajectories. This confirms the link between the two symptom clusters over time. However, a 
noteworthy exception is that three fifths of HA/Imp Class 4, showing the best change over 
time (statistically and clinically significant decrease in HA/Imp symptoms), falls into Inattn 
Class 3, the worst over time. This appears to be a dramatic illustration of the greater waning 
over time of HA/Imp symptoms compared to Inattn symptoms, which tend to be more 
persistent. The mildest HA/Imp class outnumbers the mildest Inattn class (both Class 1) 257 
to 103. This probably reflects the presence of inattentive type ADHD in the sample; the 107 
with inattentive type could have severe Inattn without HA/Imp.
Self-reported parent stress was examined as a measure of family dysfunction. Both ADHD 
symptom clusters showed a significant difference in parent stress by class. As might be 
expected, the children with highest symptom severity had the most stressed parents, and 
those with relatively lower severity had less stressed parents. This is compatible with Jester 
et al.’s report of less parental support in the worse HA/Inattn trajectory.10 A causal link 
cannot be determined from the available data, but a likely speculation is that more severe 
child symptoms disrupt family function more severely, which stresses parents more. An 
alternative speculation could involve a genetic link between a vulnerable, highly 
symptomatic child and a fragile, easily stressed parent.
Because this sample was recruited for having elevated symptoms of mania, it is possible that 
severe mood dysregulation as described by Leibenluft,41 and incorporated into the DSM-5 
diagnosis of DMDD, somehow influenced the trajectories. Actually, 26% of this sample met 
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a proxy diagnosis for DMDD at entry.25 Though ADHD was more common in the group 
who met DMDD criteria vs. the rest of the sample (79% vs. 61%), this was not significantly 
different in multivariate analyses. As might be expected, this diagnosis was more common 
(p=0.004-0.001) in class 3, the consistently worst trajectory, than in class 1, the consistently 
least severe trajectory, for both Inattn and HA/Imp.
Limitations of this study are in some ways the reverse of the strengths that make it 
interesting: the sample was not selected for ADHD, limiting the findings’ applicability to 
ADHD as such, but the fact that 526/684 had an ADHD diagnosis suggests this limitation is 
not severe. Further, not selecting for ADHD with a severity criterion may have minimized 
regression to the mean. The presence of BPSD in a large proportion introduces a confounder 
in view of the overlap between ADHD and bipolar symptoms. However, in a previous 
publication, we showed that the parent raters were able to distinguish chronic symptoms of 
inattention and hyperactivity from episodic increases in the same symptoms.42 The 
uncontrolled nature of concomitant treatment at local clinics undoubtedly introduced some 
noise into the trajectories, although we were able partially to tease this out by the analyses 
presented. Also, latent class analysis did not necessarily identify the “true” models, but 
rather those that fit optimally according to currently recommended criteria for evaluating 
model fit. Use of a different sample, measures, or schedule of assessment frequency all 
could lead to preference for a different model. However, this concern is tempered by the use 
of multiple criteria and the fact that the 3-class model of Inattn was consistent with prior 
GMMs that used only inattentive symptoms or a combination of Inattn and HA/Imp.
One of the main clinical lessons from both this set of GMM analyses and the prior GMMs is 
that we need to look beyond group mean findings to understand individual patients, their 
prognosis, and their treatment needs. For example, HA/Imp Class 3 and Class 4 start at 
approximately the same severity but diverge dramatically. Both classes had a high 
proportion of ADHD diagnoses (87.3 and 90%), so what made the difference? It is unlikely 
to be treatment with medication, because Class 3 had at least as high a rate of medication 
(stimulant and other) as Class 4. One possibility could be the difference in BPSD diagnoses 
(28.5% for Class 3 and 18% for Class 4) and baseline manic symptom scores on the YMRS 
(19.4 vs. 17.5); thus, bipolar comorbidity considerably worsens the prognosis for HA/Imp 
symptoms. However, one cannot depend on a rating scale screen to make that distinction, 
because paradoxically, Class 4 had the nominally highest proportion (94%) of ESM+, 
indicating that they passed the screening threshold on a scale proven sensitive to manic 
symptoms, yet this class had a low proportion of BPSD diagnoses. The explanation, of 
course, is the great overlap between ADHD symptoms and some manic symptoms, a 
diagnostic pitfall. It is sometimes necessary to track a patient over time to clarify the 
diagnostic issues. Episodicity of bipolar symptoms in contrast to chronicity of ADHD 
symptoms is one of the key distinctions. In regard to treatment response, both the Inattn 
Class 3 and the MTA Class 3 detect a subgroup that initially seems to respond to treatment 
with diminishing symptoms but then regresses towards baseline severity. We need to devise 
new treatments to meet the needs of that subgroup, for whom the current evidence-based 
treatments, proven on group means, are not adequate.
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• All ADHD symptoms show some improvement with time (and maturation) and 
treatment, although this does not necessarily improve function/impairment.
• Hyperactive/impulsive symptoms generally improve more over time than 
inattentive symptoms.
• We need to look beyond group mean findings to understand individual patients 
and their prognosis; subgroups of patients vary from the mean in their course.
• Although treatment is associated with overall improvement on average, analyses 
identified a subgroup with significant worsening over time despite treatment. 
New treatments, or at least creative clinical treatment planning, are needed for 
this subgroup.
• BPSD appears to interfere with the improvement of ADHD symptoms over 
time, particularly the HA/Imp symptoms. This is probably only partially a result 
of the overlap in symptoms.
• Inattentive symptoms, being more resistant to improvement from the combined 
effects of maturation and treatment, deserve additional clinical attention. As the 
patient matures, addition of cognitive-behavioral treatment, organizational or 
skills training, supportive habit training, coaching/mentoring, and/or computer-
based attention training may be considered.
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Growth mixture model latent classes of attention-deficit/hyperactivity disorder (ADHD) 
symptom trajectories in the Longitudinal Assessment of Manic Symptoms (LAMS) sample, 
not selected for ADHD, but with 526/684 having ADHD. Panel A = inattention; panel B = 
hyperactivity/impulsivity. NS = not significant.
Panel A. Inattention latent class trajectories over 3 years. Inattention Class 1 (blue, 14.8% of 
sample) and Class 3 (green, 47.5%) have significant linear (slope, p = 0.004 and 0.001) and 
quadratic (curvature, p = 0.004 and 0.001) terms for time. Class 2 (red, 37.7%) has neither 
significant slope nor curvature.
Panel B. Hyperactive/impulsive latent class symptom trajectories over 3 years. Class 1 
(blue) = 38.5%; Class 2 (red) = 4.5%; Class 3 (green) = 43%; Class 4 (purple) = 13.9%. 
Classes 3 and 4 have both significant decreasing linear (slope, [p = 0.013 and 0.005]) and 
quadratic (curvature, p = 0.044 and 0.033) terms. Class 2 shows a significant increasing 
linear slope (0.12, p = 0.049) without significant curvature. Class 1 has no significant time 
terms.
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